Where does Pegpesen sit in the long-acting GH evidence?
A network meta-analysis of five studies includes Pegpesen, Jintrolong, and somapacitan. Read the comparative findings with the limits of indirect evidence in view.
Read the study summary ↗Once-weekly growth hormone · Pediatric GHD
The science.
The evidence.
The weekly rhythm.
Pegpesen® (inpegsomatropin) is a long-acting growth hormone developed by Amoytop. Explore the product, understand the clinical program, and keep up with the research.
Source-linked information for healthcare professionals.
InpegsomatropinProduct profile / 01
Pegpesen®怡培生长激素注射液 · 益佩生®
Amoytop source ↗Once weeklySubcutaneous administration
3+ yearsChina label: pediatric GHD
391Children in the Phase III trial
52 weeksPivotal comparison with daily GH
Research watch / September 2026
A closer look at the latest.
Exploring non-GHD short stature
A 52-week Phase II basket trial in 78 children reports findings across ISS, SGA, and Turner syndrome.
Read the preliminary findings ↗A different lens on weekly dosing
The population PK/PD study explores dose titration and weight bands through simulation.
Explore the modeling paper ↗The pivotal study
A weekly regimen.
A 52-week comparison.
The randomized Phase III trial compared weekly Pegpesen with daily somatropin in treatment-naïve children with GHD. The study met its prespecified non-inferiority criterion for growth velocity.
Study design, outcomes & safety ↗Explore the reference
From molecule to practice.
Go directly to the information you need, with the source material close at hand.
01 / PRODUCT
Know the product.
Composition, presentations, approved local use, dosing, and safety information.
Product reference ↗02 / SCIENCEUnderstand the molecule.
Y-shaped PEGylation, clinical pharmacology, and the principles behind weekly exposure.
Molecule & PK/PD ↗03 / DELIVERYSee the delivery system.
TopPen I, injection workflow, and the connected tools used in treatment management.
Injector & digital care ↗Practical reference
Keep the details within reach.
Quick access to administration, monitoring, and safety topics. Clinical use should follow the locally approved prescribing information.